INTERPACE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.39 USD | -7.33% |
|
-4.14% | +28.70% |
| Mar. 07 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
| Mar. 07 | Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 22.88 | 19.1 | 12.69 | 31.18 | 4.437 | 4.693 |
| Enterprise Value (EV) 1 | 16.81 | 24 | 14.8 | 41.84 | 15.7 | 12.39 |
| P/E ratio | -1.85 x | -0.69 x | -0.43 x | -2.06 x | -0.2 x | 6.03 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.04 x | 0.79 x | 0.39 x | 0.75 x | 0.14 x | 0.12 x |
| EV / Revenue | 0.77 x | 1 x | 0.46 x | 1.01 x | 0.49 x | 0.31 x |
| EV / EBITDA | -2.36 x | -1.22 x | -0.7 x | -6.28 x | -12.3 x | 3.23 x |
| EV / FCF | -2.05 x | -5.07 x | -2.21 x | -25.8 x | -15.1 x | 2.93 x |
| FCF Yield | -48.7% | -19.7% | -45.2% | -3.87% | -6.64% | 34.1% |
| Price to Book | 0.7 x | 1.5 x | -0.44 x | -0.74 x | -0.07 x | -0.08 x |
| Nbr of stocks (in thousands) | 2,859 | 3,820 | 4,042 | 4,174 | 4,267 | 4,345 |
| Reference price 2 | 8.000 | 5.000 | 3.140 | 7.470 | 1.040 | 1.080 |
| Announcement Date | 3/21/19 | 4/22/20 | 4/1/21 | 3/31/22 | 3/27/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 21.9 | 24.08 | 32.4 | 41.31 | 31.84 | 40.21 |
| EBITDA 1 | -7.133 | -19.75 | -21.15 | -6.663 | -1.28 | 3.837 |
| EBIT 1 | -10.6 | -23.93 | -26.56 | -11.74 | -3.84 | 2.811 |
| Operating Margin | -48.4% | -99.39% | -81.96% | -28.41% | -12.06% | 6.99% |
| Earnings before Tax (EBT) 1 | -12.19 | -26.67 | -26.15 | -15.41 | -5.836 | 1.129 |
| Net income 1 | -12.19 | -26.73 | -26.45 | -14.94 | -21.96 | 0.802 |
| Net margin | -55.67% | -111% | -81.64% | -36.17% | -68.97% | 1.99% |
| EPS 2 | -4.329 | -7.253 | -7.322 | -3.618 | -5.181 | 0.1790 |
| Free Cash Flow 1 | -8.188 | -4.736 | -6.691 | -1.62 | -1.042 | 4.224 |
| FCF margin | -37.39% | -19.67% | -20.65% | -3.92% | -3.27% | 10.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 110.08% |
| FCF Conversion (Net income) | - | - | - | - | - | 526.67% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/21/19 | 4/22/20 | 4/1/21 | 3/31/22 | 3/27/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|
| Net sales 1 | 9.472 | 10.85 | 10.38 | 9.351 | 8.189 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -4.001 | -3.276 | -2.033 | -3.732 | -0.78 |
| Operating Margin | -42.24% | -30.19% | -19.59% | -39.91% | -9.52% |
| Earnings before Tax (EBT) 1 | -4.213 | -3.69 | -2.175 | -3.871 | -1.265 |
| Net income 1 | -3.561 | -3.729 | -2.247 | -3.939 | -14.21 |
| Net margin | -37.6% | -34.36% | -21.65% | -42.12% | -173.5% |
| EPS 2 | -0.8500 | -0.8900 | -0.5300 | -0.9300 | -3.350 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 4.9 | 2.11 | 10.7 | 11.3 | 7.69 |
| Net Cash position 1 | 6.07 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.2482 x | -0.0997 x | -1.599 x | -8.799 x | 2.005 x |
| Free Cash Flow 1 | -8.19 | -4.74 | -6.69 | -1.62 | -1.04 | 4.22 |
| ROE (net income / shareholders' equity) | -33.5% | -73.9% | -134% | -137% | 94.5% | -7.02% |
| ROA (Net income/ Total Assets) | -13% | -25.5% | -34.1% | -17.4% | -8.82% | 12.1% |
| Assets 1 | 93.9 | 105 | 77.47 | 85.67 | 248.9 | 6.619 |
| Book Value Per Share 2 | 11.50 | 3.320 | -7.170 | -10.10 | -14.70 | -14.20 |
| Cash Flow per Share 2 | 2.110 | 0.5900 | 0.6800 | 0.7300 | 1.120 | 0.8000 |
| Capex 1 | 0.45 | 0.13 | 1.58 | 0.35 | 0.32 | 0.47 |
| Capex / Sales | 2.05% | 0.54% | 4.86% | 0.86% | 1.01% | 1.17% |
| Announcement Date | 3/21/19 | 4/22/20 | 4/1/21 | 3/31/22 | 3/27/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +28.70% | 6.07M | |
| -14.16% | 5.6B | |
| +2.93% | 1.29B |
- Stock Market
- Equities
- IDXG Stock
- Financials Interpace Biosciences, Inc.
